150 results
8-K
EX-99.1
ALKS
Alkermes plc
24 Jul 24
Alkermes plc Reports Second Quarter 2024 Financial Results
7:05am
company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products
8-K
EX-99.1
ALKS
Alkermes plc
1 May 24
Alkermes plc Reports First Quarter 2024 Financial Results
7:05am
company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products
8-K
EX-99.1
ez70132dx1yyo
9 Apr 24
Regulation FD Disclosure
7:09am
8-K
EX-99.1
2caatjlmu9
7 Mar 24
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
7:09am
8-K
EX-99.1
aoio1xku479jgo9ow
15 Feb 24
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
ptvw8d88zfbc1p1fpw2n
14 Dec 23
Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk
6:13am
8-K
EX-99.1
f6utuleep py39m6h
15 Nov 23
Alkermes Completes Separation of Oncology Business
7:05am
8-K
y6uhwn
15 Nov 23
Alkermes Completes Separation of Oncology Business
7:05am
8-K
EX-99.1
zk3oi
31 Oct 23
Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement
5:18pm
8-K
EX-99.1
nfig1kahan9yzj1b4q
25 Oct 23
Alkermes plc Reports Third Quarter 2023 Financial Results
7:06am
8-K
EX-99.2
v2h41u cpttqi1
25 Oct 23
Alkermes plc Reports Third Quarter 2023 Financial Results
7:06am
8-K
EX-99.2
3varnvr5wpa43 47
23 Oct 23
Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress
8:27am
8-K
EX-99.1
wm7nehdg rvcjqk
23 Oct 23
Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress
8:27am
8-K
EX-99.1
jurgqqc3wfrz6cfihv4q
30 Aug 23
Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation
7:14am